Novel Parvovirus B19 Vaccine (14041)
- 详细技术说明
- None
- *Abstract
-
Features and Benefits
- Potential efficacious and safe Parvovirus B19 vaccine
- Developed by two researchers who helped successfully develop papillomavirus vaccine
- Expected to be highly immunogenic, and cost-effective
- Addresses issues of toxicity and low immunogenicity seen in previous vaccination trials for B19
*This Technology is available for licensing, further development, or industrial partnering*
Technology
Human Parvovirus B19 is a small, single-stranded DNA virus that causes Fifth disease in children. Parvovirus infection in pregnant women can lead to miscarriage or stillbirth.Researchers at the University of Louisville have created highly immunogenic virus-like particles (VLP) for the development of a new parvovirus B19 vaccine. UofL's new B19 VLP-based vaccine has been constructed to have high immunogenicity yet abrogate the toxicity found in previous B19 vaccine candidates. UofL researchers have shown that the new B19 vaccine does not bind to red blood cells or progenitor cells (a source of toxicity with previous strategies), thus it has potential to be a safe and effective vaccine capable of inducing high titer neutralizing antibodies in humans. UofL's researchers have also found that the new vaccine can be administered with alum, an improvement to adjuvants used in previous candidate vaccines.
Markets Addressed
Parvovirus B19 is a single-stranded DNA virus that belongs to the parvoviridae family. B19 can cause severe diseases in immuno-compromised individuals and in fetuses/ newborns such as erythroid erythema infectiosum, arthropathy, aplastic crisis, hydrops fetalis and intrauterine fetal death. B19 can have low immunogenicity in certain individuals resulting persistent infections. Pregnant women can also pass virus through placenta to contaminate fetus. Currently, treatment that targets B19 directly is not available. There is a great need for a vaccine to prevent B19 as well as treat patients infected by B19.
Technology Status
- IP Status: Pending PCT application ser. no. PCT/US2015/019664
- Development Status: Pre-clinical research with initial in vivo immunogenicity tests
- Fields of Use Available: All
- 国家/地区
- 美国
